197 related articles for article (PubMed ID: 6931630)
1. Acute ventricular fibrillation and death during infusion of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA).
Von Hoff DD; Elson D; Polk G; Coltman C
Cancer Treat Rep; 1980; 64(2-3):356-8. PubMed ID: 6931630
[No Abstract] [Full Text] [Related]
2. Multiple ventricular extrasystoles following administration of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA).
Falkson G
Cancer Treat Rep; 1980; 64(2-3):358. PubMed ID: 6157470
[No Abstract] [Full Text] [Related]
3. Neurologic and cardiac rhythm abnormalities associated with 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) therapy.
Legha SS; Latreille J; McCredie KB; Bodey GP
Cancer Treat Rep; 1979; 63(11-12):2001-3. PubMed ID: 526933
[No Abstract] [Full Text] [Related]
4. [Case of refractory acute myeloblastic leukemia who achieved complete remission by a new anti-leukemic agent, 4'-(9-acridinylamino) methanesulfon-m-anisidide (AMSA)].
Nagura E; Kawashima K; Suzuki H; Ohno R; Yamada K; Yokomaku S; Ogawa M
Rinsho Ketsueki; 1983 May; 24(5):632-8. PubMed ID: 6577212
[No Abstract] [Full Text] [Related]
5. A phase II evaluation of m-AMSA, 4'-(9-acridinylamino) methanesulfon-m-anisidide, in patients with breast cancer.
Currie VE; Howard J; Wittes R
Cancer Clin Trials; 1981; 4(3):249-51. PubMed ID: 6895189
[TBL] [Abstract][Full Text] [Related]
6. Phase I evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) by a weekly iv dose schedule.
Woodcock TM; Schneider RJ; Young CW
Cancer Treat Rep; 1980 Jan; 64(1):53-5. PubMed ID: 6892893
[TBL] [Abstract][Full Text] [Related]
7. Phase II evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced colorectal carcinoma.
Carroll DS; Kemeny N; Lynch G; Wookcock T
Cancer Treat Rep; 1980; 64(10-11):1149-50. PubMed ID: 6893951
[No Abstract] [Full Text] [Related]
8. Phase II. Evaluation of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (AMSA) in patients with advanced sarcoma.
Sordillo PP; Magill GB; Gralla RJ; Golbey RB
Cancer Treat Rep; 1980; 64(10-11):1129-30. PubMed ID: 6893950
[No Abstract] [Full Text] [Related]
9. Phase II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with metastatic renal cell carcinoma.
Van Echo DA; Markus S; Aisner J; Wiernik PH
Cancer Treat Rep; 1980; 64(8-9):1009-10. PubMed ID: 6893810
[No Abstract] [Full Text] [Related]
10. Phase I and II trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide in patients with acute leukemia.
Arlin ZA; Sklaroff RB; Gee TS; Kempin SJ; Howard J; Clarkson BD; Young CW
Cancer Res; 1980 Sep; 40(9):3304-6. PubMed ID: 6933002
[TBL] [Abstract][Full Text] [Related]
11. Phase I-II study of m-AMSA administered as a continuous infusion.
Micetich KC; Zwelling LA; Gormley P; Young RC
Cancer Treat Rep; 1982 Oct; 66(10):1813-7. PubMed ID: 6897013
[TBL] [Abstract][Full Text] [Related]
12. 4'-(9-Acridinylamino) methanesulfon-m-anisidide (AMSA): a new drug effective in the treatment of adult acute leukemia.
Legha SS; Keating MJ; Zander AR; McCredie KB; Bodey GP; Freireich EJ
Ann Intern Med; 1980 Jul; 93(1):17-21. PubMed ID: 6930826
[TBL] [Abstract][Full Text] [Related]
13. Phase II. Trial of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in the treatment of advanced non-Hodgkin's lymphoma.
Warrell RP; Straus DJ; Young CW
Cancer Treat Rep; 1980; 64(10-11):1157-8. PubMed ID: 6893952
[TBL] [Abstract][Full Text] [Related]
14. 4'-(9-acridinylamino)methane-sulfon-m-anisidide (m-AMSA) and 5-azacytidine (AZA) in the treatment of relapsed adult acute leukemia.
Kahn SB; Sklaroff R; Lebedda J; Conroy JF; Bulova S; Brodsky I
Am J Clin Oncol; 1983 Aug; 6(4):493-502. PubMed ID: 6191561
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of 4'-(9-acridinylamino) methanesulfon-m- anisidide (AMSA) in metastatic melanoma.
Legha SS; Hall SW; Powell KC; Burgess MA; Benjamin RS; Gutterman JU; Bodey GP
Cancer Clin Trials; 1980; 3(2):111-4. PubMed ID: 6893573
[TBL] [Abstract][Full Text] [Related]
16. [Clinical activity of m-Amsa and the combination of m-Amsa with cytosine arabinoside].
Weil M; Auclerc MF; Schaison G; Auclerc G; Daubrisson A; Degos L; Caro J; Marty M; Jacquillat GI
Nouv Presse Med; 1982 Oct; 11(39):2911-4. PubMed ID: 6755389
[TBL] [Abstract][Full Text] [Related]
17. Phase II evaluation of 4'-(9-acridinylamino)methanesulfon-m-anisidide (AMSA) in patients with non-small cell lung cancer.
Casper ES; Gralla RJ; Kelsen DP; Natale RB; Sordillo P; Houghton A
Cancer Treat Rep; 1980; 64(2-3):345-7. PubMed ID: 6893294
[No Abstract] [Full Text] [Related]
18. Ventricular fibrillation following AMSA. Uncomplicated retreatment following correction of hypokalemia.
McLaughlin P; Salvador PG; Cabanillas F; Legha SS
Cancer; 1983 Aug; 52(3):557-8. PubMed ID: 6688037
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of 4'-(9-acridinylamino) methanesulfon-m-anisidide (m-AMSA, NSC 249992) on human tumors in nude mice.
Sordillo PP; Helson L; Lesser M
Cancer Clin Trials; 1980; 3(4):385-9. PubMed ID: 6893575
[TBL] [Abstract][Full Text] [Related]
20. Phase II trial of amsacrine (m-AMSA) in advanced ovarian carcinoma.
Dombernowsky P; Siegenthaler P; Somers R; Hansen HH
Eur J Cancer Clin Oncol; 1982 Jan; 18(1):71-4. PubMed ID: 6896306
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]